Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol

British Journal of Radiology

Volumn 77, Issue 917, 2004, Pages 377-386

  Mott, J H ^a,b   Livsey, J E ^a   Logue, J P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLLIMATOR; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MODULATION; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; STATISTICAL ANALYSIS; TARGET ORGAN; TREATMENT PLANNING;

CLINICAL PROTOCOLS; DOSE FRACTIONATION; FEMUR HEAD; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; URINARY BLADDER;

EID: 2642569200     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/66104316     Document Type: Article

References (24)

1. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: five-year outcomes, treatment optimisation, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-10.
2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleschner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radition therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:9491-500.
3. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson Phase III randomised trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
4. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatramen ES, Levegrun S, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-98.
5. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomised radiotherapy dose escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-11.
6. Michalski J, Purdy J, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;46:391-402.
7. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.
8. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
9. Brenner DJ. Towards optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:315-6.
10. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumours really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
11. D'Souza WD, Thames HD. Is the α/β ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 2001;51:1-3.
12. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;55:194-203.
13. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2001;49:1522-3.
14. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/ fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-93.
15. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:904-12.
16. Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV, et al. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys 2002;53:1106-10.
17. Read G, Pointon RC. Retrospective study of radiotherapy in early carcinoma of prostate. Br J Urol 1989;63:191-5.
18. Logue JP, Livsey JE, Cowan RA, Wiley JP, Swindell R, Read G, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: 5 year outcome analysis. Int J Radiat Oncol Biol Phys 2002;54:S189.
19. Livsey JE, Routledge J, Burns M, Swindell R, Cowan RA, Logue JP, et al. Scoring of treatment related late effects in prostate cancer. Radiother Oncol 2002;65:109-21.
20. MRC (Medical Research Council). RT01: a randomised trial of high dose therapy in localised cancer of the prostate using conformal radiotherapy techniques. MRC radiotherapy working party, London. 1998.
21. Amer AM, Mott J, Mackay RI, Williams PC, Hendry JH, Livsey J, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;56:199-207.
22. Stein J, Mohan R, Wang XH, Bortfeld T, Wu Q, Preiser K, et al. Number and orientations of beams in intensity-modulated radiation treatments. Med Phys 1997;24:149-60.
23. ICRU (International Commission on radiation Units, Measurements). Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). ICRU Report 62. 1999.
24. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.